Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17706548 | 0.81 | POLB (0.51) | POLBSMN1; SMN2ALDH1A1KMT2ARAB9A | |
| SCHEMBL11010839 | 0.80 | — | — | |
| SCHEMBL152156 | 0.80 | HPGD (0.40) | SMN1; SMN2ALDH1A1KMT2AKDM4ECYP1A2 | |
| SCHEMBL13544920 | 0.79 | POLB (0.42) | POLBSMN1; SMN2ALDH1A1KMT2ARAB9A | |
| SCHEMBL28364819 | 0.79 | POLB (0.39) | POLBSMN1; SMN2ALDH1A1KMT2ARAB9A | |
| SCHEMBL20321273 | 0.78 | — | — | |
| Water SCHEMBL2745045 | 0.78 | HPGD (0.39) | SMN1; SMN2ALDH1A1KMT2AKDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL11591950 | 0.78 | HPGD (0.39) | SMN1; SMN2ALDH1A1KMT2AKDM4ETDP1 | |
| SCHEMBL16861500 | 0.78 | PARP1 (0.40) | ALDH1A1KDM4ETDP1HPGD | |
| SCHEMBL20630522 | 0.78 | PLK1 (0.38) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018118734-A1 | HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME CORP. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2018-02-01 | — | — | US | disclosed |
| US-20170360786-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9732070-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20170152246-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2017-06-01 | — | — | US | disclosed |
| US-9566278-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160257681-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-9321763-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20160058760-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2016-03-03 | — | — | US | disclosed |
| US-9181222-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9169249-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140329842-A1 | Protein Kinase C Inhibitors and Uses Thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140275055-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2014-09-18 | — | — | US | disclosed |
| US-8710223-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2012-01-26 | — | — | US | disclosed |
| US-20110130415-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | disclosed |
| US-7250389-B1 | Antifungal compound and process for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-07-31 | — | — | US | disclosed |
| US-7250389-B1 | Antifungal compound and process for producing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329842-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | POLB 1944/4885SMN1; SMN2 1709/4885ALDH1A1 4361/4885 |
| US-20170360786-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | POLB 1944/4885SMN1; SMN2 1709/4885ALDH1A1 4361/4885 |
| US-20110130415-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | POLB 1944/4885SMN1; SMN2 1709/4885ALDH1A1 4361/4885 |
| US-20120022092-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | POLB 1944/4885SMN1; SMN2 1709/4885ALDH1A1 4361/4885 |
| US-20170152246-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | POLB 1944/4885SMN1; SMN2 1709/4885ALDH1A1 4361/4885 |
| US-20140275055-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | POLB 1944/4885SMN1; SMN2 1709/4885ALDH1A1 4361/4885 |
| US-10005777-B2 | Protein kinase C inhibitors and uses thereof | PRKCH, PRKCA, PRKCB | POLB 1944/4885SMN1; SMN2 1709/4885ALDH1A1 4361/4885 |
| US-20160058760-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | POLB 1944/4885SMN1; SMN2 1709/4885ALDH1A1 4361/4885 |
| US-20160257681-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | POLB 1944/4885SMN1; SMN2 1709/4885ALDH1A1 4361/4885 |
| US-20180030050-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | POLB 1944/4885SMN1; SMN2 1709/4885ALDH1A1 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.